Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term breast cancer. Found 123 abstracts

no pagination
Maclean JC, Halpern MT, Hill SC, Pesko MF. The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications. Health Serv Res. 2020 Jun;55(3):399-410.
Melchior NM, Sachs DB, Gauvin G, Chang C, Wang CE, Sigurdson ER, Daly JM, Aggon AA, Hayes SB, Obeid EI, Bleicher RJ. Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?. Cancer medicine. 2020 Feb 25;9(8):2742-51.   PMCID: PMC7163083
Pal T, Agnese D, Daly M, La Spada A, Litton J, Wick M, Klugman S, Esplin ED, Jarvik GP, Professional P, Guidelines C. Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020 Apr;22(4):681-5.
Williams AD, Bleicher RJ, Ciocca RM. Breast Cancer Risk, Screening, and Prevalence Among Sexual Minority Women: An Analysis of the National Health Interview Survey. LGBT Health. 2020 Feb;7(2):109-18.
Blackwell KL, Zaman K, Qin S, Tkaczuk KH, Campone M, Hunt D, Bryce R, Goldstein LJ, Study G. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study. Clin Breast Cancer. 2019 Apr;19(2):97-104 e4.
Reese JB, Smith KC, Handorf E, Sorice K, Bober SL, Bantug ET, Schwartz S, Porter LS. A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. Journal of psychosocial oncology. 2019 Mar;37(2):242-63.   PMCID: PMC6476670
West AH, Knollman H, Dugan J, Hedeker D, Handorf EA, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghahi A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, Obeid E, Churpek JE. Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer medicine. 2019 Aug 12;8(12):5609-18.   PMCID: PMC6745828
Zeinomar N, Phillips KA, Daly MB, Milne RL, Dite GS, MacInnis RJ, Liao Y, Kehm RD, Knight JA, Southey MC, Chung WK, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S, Andrulis IL, Buys SS, John EM, Hopper JL, Terry MB. Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort. International journal of cancer. 2019 Feb 06;145(2):370-9.   PMCID: PMC6525034
Martin JM, Goldstein LJ. Profile of abemaciclib and its potential in the treatment of breast cancer. Onco Targets Ther. 2018 Aug;11:5253-9.   PMCID: PMC6120573
O'Malley D, Dewan AA, Ohman-Strickland P, Gundersen DA, Miller SM, Hudson SV. Determinants of Patient Activation in a Community Sample of Breast and Prostate Cancer Survivors. Psychooncology. 2018 Jan 30;27(1):132-40.   PMCID: PMC5568503
Patel RS, Wen KY, Aggarwal R. Demographic Pattern and Hospitalization Outcomes of Depression among 2.1 Million Americans with Four Major Cancers in the United States. Medical sciences (Basel, Switzerland). 2018 Oct 24;6(4).   PMCID: PMC6313571
Churilla TM, Egleston B, Bleicher R, Dong Y, Meyer J, Anderson P. Disparities in the Local Management of Breast Cancer in the US according to Health Insurance Status. Breast J. 2017 Mar;23(2):169-76.
Dias MF, Blumenstein R, Russo J. Use of laser capture microdissection allows detection of loss of heterozygosity in chromosome 9p in breast cancer. Oncology Letters. 2017 May;13(5):3831-6.   PMCID: PMC5431386
Manne SL, Kashy D, Siegel SD, Heckman CJ. Group therapy processes and treatment outcomes in 2 couple-focused group interventions for breast cancer patients. Psychooncology. 2017 Dec;26(12):2175-85.   PMCID: PMC5548627
O'Malley D, Dewan AA, Ohman-Strickland P, Gundersen DA, Miller SM, Hudson SV. Determinants of Patient Activation in a Community Sample of Breast and Prostate Cancer Survivors. Psychooncology. 2017 Jan 30;.
Wen KY, Ma XS, Fang C, Song Y, Tan Y, Seals B, Ma GX. Psychosocial correlates of benefit finding in breast cancer survivors in China. Journal of health psychology. 2017 Nov;22(13):1731-42.
Wu D, Si M, Xue HY, Wong HL. Nanomedicine applications in the treatment of breast cancer: current state of the art. International journal of nanomedicine. 2017 Aug;12:5879-92.   PMCID: PMC5566389
Zhang FF, Haslam DE, Terry MB, Knight JA, Andrulis IL, Daly MB, Buys SS, John EM. Dietary isoflavone intake and all-cause mortality in breast cancer survivors: The Breast Cancer Family Registry. Cancer. 2017 Jun;123(11):2070-9.   PMCID: PMC5444962
Bleicher RJ, Ruth K, Sigurdson ER, Daly JM, Boraas M, Anderson PR, Egleston BL. Breast conservation versus mastectomy for patients with T3 primary tumors (>5 cm): A review of 5685 medicare patients. Cancer. 2016 Jan;122(1):42-9.   PMCID: PMC4707052
Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology. 2015 Sep;4(9):e985930.   PMCID: PMC4570112
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term breast cancer

breast cancer oncology prostate cancer surgery Brca2 patient activation survivorship Medicaid Brca1 women's health hybridization Novartis Genentech-and Genomic Health JMM has no conflicts of interest in this insurance hereditary breast and ovarian cancer syndrome heterogeneity hematologic toxicity Chinese interventions Seer couple therapy molecular analysis Cdk4 breast cancer survivors human tumors Healthcare Disparities Female genetic heterogeneity Tyrosine kinase inhibitor Combination drug therapy neoadjuvant chemotherapy cancer neutropenic fever Segmental Mastectomy breast neoplasms breast radiotherapy Trastuzumab segmental mastectomy Tnbc work Adult epidemiology familial risk soy Middle Aged sexual minority women cdkn2 gene radiation therapy sexuality tumor infiltrating lymphocytes bisexual psychotherapy Breast Neoplasms survival rate mortality genetic testing SEER Program treatment outcome epithelial-cells ductal carcinoma loss of heterozygosity targeted delivery lung cancer inpatient psychiatry colorectal cancer Registries Young Adult cancer survivors breast surgery therapy public insurance Insurance Coverage biomarker in-situ allelic loss survival sexual dysfunction Her2 statistics & numerical data feasibility studies benign breast disease isoflavone Adolescent abemaciclib nanomedicine United States mammography tumor microenvironment cyclin D1 drug resistance Health Insurance psychosocial couples' groups Mdd clinical practice patterns Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm lesbian prescription medications multigene panels laser microdissection metastasis working alliance Neratinib Medically Uninsured breast mortality 6 differences-in-differences cancer management breast pathology group processes chromosome 9p breast-conserving surgery drug therapy
Last updated on Saturday, July 04, 2020